We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 321

Leave to appeal to SCC granted for a section 8 damages case

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

The Supreme Court has granted leave in a proceeding pursuant to section 8 of the PM(NOC) Regulations. Some of the issues to be decided in this

Appeal decision addresses the promise doctrine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

This decision relates to two appeals that were heard together and the reasons apply to both. The decision set out the parties’ positions and then

Doctrine of bona fide purchaser for value without notice applies to patent rights

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2012

This case involves a dispute over who owned certain patent rights

Court determines beneficial ownership of several patents as part of action for wrongful conduct

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 15 2014

This was an action by the Plaintiff for relief arising from the allegedly wrongful conduct of the Defendant Li. The Plaintiff claimed that Li

Patent found invalid on basis of lack of utility, sound prediction and obviousness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 3 2012

This decision relates to an impeachment action and an infringement action that were consolidated

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Pleadings amendment to a damages reference not allowed found to be a collateral attack on the final judgment

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

Apotex moved to file an amended Responding Statement of Issues on a reference pursuant to Rule 153. According to the Court, Apotex wants to argue

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 22 2013

A Member of the Trade-marks Opposition Board (Member) refused the registration of MACDIMSUM for a variety of food and drink items (the Trade-mark

Patent Appeal Board considers solution to problem non-obvious

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 17 2012

The Examiner rejected the patent application for a system for preparing a schedule for travel on the basis that the claims are obvious

Compound patent found valid in face of allegations of lack of utilitysound prediction and insufficiency

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 27 2013

Apotex and Novopharm started actions to impeach Novartis’ patent covering the compound imatinib, sold under the brand name GLEEVEC. They then sent